Functional Evaluation of P-gp and Bcrp at the Murine Blood-Cerebrospinal Fluid Barrier
Pharmaceutical Research · 2023
DOI: 10.1007/s11095-023-03598-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Research, 2023. Verfasst von Austin Sun und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, University of Washington, H272 Health Sciences Building, Seattle, WA, 98195-7610, USA. Hauptthemen laut MEDLINE: ATP Binding Cassette Transporter, Subfamily B, Member 1, Blood-Brain Barrier. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, Foundation for the National Institutes of Health.
Abstract (Originalsprache)
PURPOSE: The brain is protected from circulating metabolites and xenobiotics by the blood-brain barrier (BBB) and the blood-cerebrospinal fluid (CSF) barrier. Previous studies report that P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp) are expressed apically or subapically at the blood-CSF barrier (BCSFB), implying a paradoxical function to mediate blood-to-CSF transport of xenobiotics. As evidence of P-gp and Bcrp activity at the BCSFB is limited, the goal of this study is to investigate functional activity of P-gp and Bcrp at the murine BCSFB using a live tissue imaging approach. METHODS: The choroid plexuses (CP) forming the BCSFB were freshly isolated from mouse brain ventricles and incubated with fluorescent probes calcein-AM and BODIPY FL-Prazosin. Using quantitative fluorescence microscopy, the functional contributions of Bcrp and P-gp were examined using inhibitors and mice with targeted deletion of the Abcb1a/b or Abcg2 gene. RESULTS: Apical transport of calcein-AM in choroid plexus epithelial (CPE) cells is sensitive to inhibition by elacridar and Ko143 but is unaffected by P-gp deletion. In wild-type mice, elacridar increased CPE accumulation of BODIPY FL-Prazosin by 220% whereas deletion of Bcrp increased BODIPY FL-Prazosin accumulation by 43%. There was no change in Mdr1a/1b mRNA expression in CP tissues from the Bcrp-/- mice. CONCLUSIONS: This study demonstrated functional activity of Bcrp at the BCSFB apical membrane and provided evidence supporting an additional contribution by P-gp. These findings contribute to the understanding of transport mechanisms that regulate CSF drug concentrations, which may benefit future predictions of CNS drug disposition, efficacy, and toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, University of Washington, H272 Health Sciences Building, Seattle, WA, 98195-7610, USA.
- Department of Pharmaceutics, University of Washington, H272 Health Sciences Building, Seattle, WA, 98195-7610, USA. jowang@uw.edu.
Förderung
- NIA NIH HHS
- Foundation for the National Institutes of Health
Zitieren
APA
Sun, A., & Wang, J. (2023). Functional Evaluation of P-gp and Bcrp at the Murine Blood-Cerebrospinal Fluid Barrier. Pharmaceutical Research. https://doi.org/10.1007/s11095-023-03598-7
Vancouver
Sun A, Wang J. Functional Evaluation of P-gp and Bcrp at the Murine Blood-Cerebrospinal Fluid Barrier. Pharmaceutical Research. 2023. doi:10.1007/s11095-023-03598-7
BibTeX
@article{Sun2023,
author = {Sun, Austin and Wang, Joanne},
title = {Functional Evaluation of P-gp and Bcrp at the Murine Blood-Cerebrospinal Fluid Barrier},
journal = {Pharmaceutical Research},
year = {2023},
doi = {10.1007/s11095-023-03598-7}
}
EUVIMED